Immunotherapy: past, present and future

@article{Waldmann2003ImmunotherapyPP,
  title={Immunotherapy: past, present and future},
  author={Thomas A. Waldmann},
  journal={Nature Medicine},
  year={2003},
  volume={9},
  pages={269-277}
}
  • T. Waldmann
  • Published 1 March 2003
  • Medicine
  • Nature Medicine
Harnessing the immune system to treat chronic infectious diseases or cancer is a major goal of immunotherapy. Among others, impediments to this aim include host failure to identify tumor antigens, tolerance to self and negative immunoregulatory mechanisms. But with recent progress, active and passive immunotherapy are proving themselves as effective therapeutic strategies. 
Immunotherapy in clinical medicine: historical perspective and current status.
In humans, the immune system is a complex organ system involving cells and soluble mediators whose function is, essentially, protection. However, disequilibrium in this intricate system leads toExpand
Progress on new vaccine strategies for the immunotherapy and prevention of cancer.
TLDR
This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer. Expand
Immunotherapy in acute leukemia.
  • W. Leung
  • Medicine
  • Seminars in hematology
  • 2009
TLDR
The latest concepts in antitumor immunology and its application in the treatment of cancer, with particular focus on acute leukemia are reviewed. Expand
Frontiers in nephrology: T cell memory as a barrier to transplant tolerance.
Immunologic memory, or the ability to respond more rapidly and effectively to the previously encountered pathogens, represents a fundamental feature of the adaptive immune system. Such memoryExpand
Vaccines and Immunotherapeutics for the Treatment of Malignant Disease
TLDR
A number of immunotherapeutic strategies have arisen for the treatment of malignant disease, including various vaccination schemes, cytokine therapy, adoptive cellular therapy, and monoclonal antibody therapy. Expand
The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer
TLDR
Among immunomodulators, checkpoint inhibitors are used to enhance the immune system and significantly improve therapeutic results of advanced disease, mounting tumor progression. Expand
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
TLDR
Evidence is presented to show that Treg cells play an important role in suppressing antitumor immunity since the deletion of these cells, when used in combination with LEC or costimulatory fusion proteins, produced profound and effective treatment with sustained memory. Expand
Immunotherapy as an Option for Cancer Treatment
TLDR
Pre-clinical research using ex vivo and in vivo approaches demonstrates the promise of numerous novel strategies for the immunotherapy of cancer, including therapies based on the blockade of immune checkpoint molecules. Expand
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
TLDR
Although “immunotherapy” is habitually associated with the treatment of cancer, this review accentuates the evolving role of key targeted immune interventions that are approved, as well as those in development, for various cancers and infectious diseases. Expand
Effective cancer therapy through immunomodulation.
  • T. Waldmann
  • Biology, Medicine
  • Annual review of medicine
  • 2006
TLDR
Checkpoints being targeted include CTLA-4 and PD1 that are negative signaling receptors expressed on activated T cells, CD4+CD25+ Foxp3-expressing Tregs (suppressor T cells), IL-2-mediated activation-induced cell death (AICD), and the cytokine TGFbeta. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 93 REFERENCES
Vaccines: Spinning molecular immunology into successful immunotherapy
  • D. Pardoll
  • Biology, Medicine
  • Nature Reviews Immunology
  • 2002
TLDR
Some of the most promising molecular and cellular targets for immunotherapy are reviewed and approaches that use these targets to amplify immune responses and potentially break antigen-specific tolerance are discussed, providing a blueprint for the development of successful immunotherapy over the next decade. Expand
The prime-boost strategy: exciting prospects for improved vaccination.
Abstract Unprecedented levels of cell-mediated immunity can be stimulated by the consecutive use of DNA vaccines and attenuated poxvirus vectors encoding similar heterologous antigens. This may offerExpand
Immunotherapy of human cancer: lessons from mice
TLDR
It may be necessary to consider different endpoints and objectives when evaluating the efficacy of these newer approaches to immunotherapies for cancer, as well as the approval process designed for testing drugs. Expand
Improving the efficacy of antibody-based cancer therapies
TLDR
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer, and many innovative approaches stand poised to improve the efficacy of antibody-based therapies. Expand
Tumor antigens recognized by T cells.
TLDR
The priority now is to demonstrate that immunization against tumor-specific antigens is clinically valuable, according to Thierry Boon and colleagues. Expand
Strategies for designing and optimizing new generation vaccines
TLDR
Only recently has vaccinology returned to the realm of immunology, because a new understanding of immune mechanisms has allowed translation of basic discoveries into vaccine strategies. Expand
Human tumor antigens recognized by T cells.
The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltratingExpand
[Monoclonal antibodies in diagnosis and therapy].
The value of monoclonal antibodies (mAb) produced against renal, bladder and prostate cancer antigens is demonstrated. These mAb allow a molecular classification of urological cancers as well asExpand
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
TLDR
Newly emerging data suggest that inhibitory signals mediated by CTLA-4 not only can determine whether T cells become activated, but also can play a role in regulating the clonal representation in a polyclonal response. Expand
Therapeutic antibodies: Magic bullets hit the target
After decades of disappointment, antibodies are finally emerging as viable — if expensive — drugs. Trisha Gura finds biotech start-ups and pharmaceutical giants rushing to claim a piece of the action.
...
1
2
3
4
5
...